DDInter779 DDInter927
An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Foscarnet {u} (Compound) binds {v} (Gene) SLC22A6
Foscarnet {u} (Compound) is included by {v} (Pharmacologic Class) DNA Polymerase Inhibitors
Foscarnet {u} (Compound) causes {v} (Side Effect) Blood urea increased
Foscarnet {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Foscarnet {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palonosetron
Foscarnet {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisone
Foscarnet {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Foscarnet {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Foscarnet (Compound) binds SLC22A6 (Gene)
Foscarnet (Compound) is included by DNA Polymerase Inhibitors (Pharmacologic Class)
Foscarnet (Compound) causes Blood urea increased (Side Effect)
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Prednisone
Foscarnet may lead to a major life threatening interaction when taken with Iohexol
Foscarnet may lead to a major life threatening interaction when taken with Anagrelide